Dr. Jean Bourbeau is a clinician scientist, professor, and researcher at McGill University and a Senior Scientist at the Research Institute McGill University Health Centre. He is a Fellow of the Canadian Academy of Health Sciences (FCAHS) and has received numerous prestigious awards, including the « Distinguished Scientist Award » from McGill University (2020-2025) and the « Distinguished CHEST Educator » from the American College of Chest Physicians (2017-2022).
Internationally recognized for his expertise in Chronic Obstructive Pulmonary Disease (COPD), he actively participates in various scientific committees and has served as the President and remains on the board of the Canadian Thoracic Society (CTS). His research includes notable contributions like the « Living Well with COPD » self-management program and the Canadian Cohort Obstructive Lung Disease (CanCOLD) prospective study, over 15M$ grant support since 2009, CIHR grants, >100 sub-studies and >80 publications. Over the last decades, he has secured substantial research funding, published over 400 papers, reviews, and chapters, and his work has significantly influenced clinical practice worldwide.
He is the principal investigator for various investigator initiated clinical trials, addressing both non-pharmacological interventions and drug or device interventions for COPD patients. His dedication extends to advancing clinical trial training platforms as he leads the CIHR Clinical Training Trial Platform, CANTRAIN, with 11.3 million dollars in funding (2022-2025).
Dr. Bourbeau has made significant contributions to national and international guidelines, including the GOLD Reports, CTS COPD pharmacotherapy Guidelines, American College of Chest Physicians/CTS Guidelines on prevention of COPD exacerbations, and American Thoracic/European Respiratory Society Guidelines on Pulmonary Rehabilitation.
